Isodose moderately hypofractionated radiotherapy allows patients to undergo just 4-5 weeks of treatment, compared to conventional therapy that can take around 8. 

These findings could help guide the development of new treatments for psychiatric and neurological disorders.  

Howard Herrmann, MD,  MSCAI, Hospital of the University of Pennsylvania, and lead invesigator for the SMART trial, explains details on the 2-year data comparing the Evolut vs. Sapien 3 for TAVR in small annulus patients.

Researchers in Toronto used MRI scans to measure the brain as it heals after injury. They found damage persists for a year after athletes are medically cleared to return to the field. 

A group of researchers used 3D imaging to examine changes in the skulls of mice as they age, revealing a new perspective on how older bones heal.

While the policy of President Donald Trump is to axe research on transgender issues and DEI, scientists who spoke to the Boston Globe said their work does not run up against those restrictions. 

Trial results thus far indicate the drug can significantly extend progression-free survival compared to current standard of care treatments.

Two separate groups have published new research comparing early AVR with clinical surveillance for the treatment of asymptomatic severe aortic stenosis. Overall, the two groups found, early treatment was associated with multiple benefits—and no added risk of harm.